Private company
TFF Pharmaceuticals, Inc.
American pharmaceutical preparations company based in Fort Worth.
Last updated Oct 18, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2023
-2983.4%Operating margin3
-2894.7%Net margin3
48.0%Revenue growth, 20233
-222.0%Return on equity3
-$16.1MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2023
- Research and development100¢$12.1M
- Interest0¢$14.5K
Out of $733.9K in revenue.3 The company lost money this year.
Financial statements
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenue | $88.2K4 | $495.8K3 | $733.9K3 | ||||
| Research and development | $848.8K5 | $8.8M6 | $10.7M7 | $21.3M4 | $18.5M3 | $12.1M3 | |
| Operating income | -$3.9M5 | -$12.0M6 | -$18.7M7 | -$31.8M4 | -$31.8M3 | -$21.9M3 | |
| Interest | $14.5K3 | ||||||
| Net income | -$3.8M5 | -$11.9M6 | -$18.6M7 | -$31.0M4 | -$31.8M3 | -$21.2M3 | |
| Earnings per share | -$1.254 | -$26.493 | -$11.853 | ||||
| Earnings per share (diluted) | -$1.254 | -$26.493 | -$11.853 |
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Cash | $10.3M6 | $28.1M6 | $35.3M7 | $33.8M4 | $16.6M3 | $5.5M3 | |
| Current assets | $10.3M5 | $29.2M6 | $37.6M7 | $38.8M4 | $19.0M3 | $7.6M3 | |
| Total assets | $10.4M5 | $29.2M6 | $38.7M7 | $40.7M4 | $24.1M3 | $12.0M3 | |
| Current liabilities | $1.2M5 | $410.6K6 | $1.3M6 | $2.0M4 | $1.1M3 | $2.4M3 | |
| Total liabilities | $1.2M5 | $1.5M6 | $1.3M7 | $2.0M4 | $1.2M3 | $2.5M3 | |
| Shareholders’ equity | -$1.8K5 | -$3.2M6 | $27.6M7 | $37.3M4 | $38.7M3 | $22.9M3 | $9.6M3 |
| Shares outstanding | 4.0M shares5 | 18.5M shares6 | 22.5M shares7 | 25.4M shares4 | 1.4M shares3 | 2.4M shares3 |
Leadership
Who has led TFF Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
20202025
- Chief executive officerHarlan F. Weisman Dec 6, 2022 to Jul 8, 202410
- Chief executive officerGlenn R. Mattes Oct 24, 2019 to May 17, 202211
- PresidentHarlan F. Weisman Dec 6, 2022 to Jul 8, 202410
- PresidentGlenn R. Mattes Oct 24, 2019 to May 17, 202211
- Chief financial officerKirk Allen Coleman Oct 24, 2019 to Jul 8, 202412
- Chief operating officerChristopher Cano Sep 29, 2020 to Sep 24, 202113
Board members and other officers (14)
- Chief Medical OfficerZamaneh Mikhak Jan 20, 2023 to Jul 8, 202414
- Chief Science OfficerJames Brian Windsor Oct 24, 2019 to Dec 9, 202015
- Board memberCatherine Chai-Zon Lee Dec 4, 2023 to Jul 8, 202416
- Board memberMichael A. Patane Dec 4, 2023 to Apr 22, 202417
- Board memberThomas Braxton King Dec 15, 2023 to Jul 8, 202418
- Board memberBrandi Roberts Apr 4, 2022 to Jul 8, 202419
- Board memberMalcolm Fairbairn Feb 5, 2020 to May 19, 202120
- Board memberAaron G.l. Fletcher Oct 24, 2019 to Dec 30, 202221
- Board memberGlenn R. Mattes Oct 24, 2019 to May 17, 202211
- Board memberHarlan F. Weisman Oct 24, 2019 to Jul 8, 202422
- Board memberJames Brian Windsor Oct 24, 2019 to Dec 9, 202015
- Board memberRandy H. Thurman Oct 24, 2019 to Sep 30, 202223
- Board memberRobert S. Mills Oct 24, 2019 to Jul 8, 202424
- Board memberStephen Rocamboli Oct 24, 2019 to Jul 8, 202425
Timeline
Filings
181 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 45 major events, 56 insider forms, 13 large holders, 1 private raises, 53 other. The latest 20:
- Mar 7, 2025EFFECT EDGAR
- Mar 7, 2025EFFECT EDGAR
- Mar 7, 2025EFFECT EDGAR
- Mar 7, 2025EFFECT EDGAR
- Mar 6, 202525 EDGAR
- Mar 6, 2025S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
- Mar 6, 2025S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
- Mar 6, 2025S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
- Mar 6, 2025POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 EDGAR
- Mar 6, 2025POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 EDGAR
- Mar 6, 2025POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 EDGAR
- Mar 6, 2025POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 EDGAR
- Mar 6, 20258-K CURRENT REPORT EDGAR
- Feb 4, 2025DEFA14A DEFINITIVE ADDITIONAL MATERIALS EDGAR
- Feb 3, 20258-K CURRENT REPORT EDGAR
- Dec 23, 2024DEF 14A PROXY STATEMENT EDGAR
- Dec 11, 2024PRE 14A PROXY STATEMENT EDGAR
- Dec 10, 20248-K CURRENT REPORT EDGAR
- Nov 20, 202410-Q QUARTERLY REPORT EDGAR
- Nov 19, 2024SC 13G/A EDGAR
The 181 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 13 such filings since October 2021, the latest 10:
- Nov 19, 2024SC 13G/A
- Nov 14, 2024SC 13G
- May 8, 2024SC 13G
- May 8, 2024SC 13G/A
- Feb 14, 2024SC 13G/A
- Feb 14, 2023SC 13G/A
- Feb 13, 2023SC 13G/A
- Feb 9, 2023SC 13G/A
- Nov 28, 2022SC 13G
- Nov 23, 2022SC 13G
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Money raised
Private offerings the company reported to the SEC on Form D.
- Mar 22, 2024Filed a private offering of securities Form D: $1.2 million offered in all Form D
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARCatherine Chai-Zon Lee, Board member
- 17SEC EDGARMichael A. Patane, Board member
- 18SEC EDGARThomas Braxton King, Board member
- 19SEC EDGARBrandi Roberts, Board member
- 20SEC EDGARMalcolm Fairbairn, Board member
- 21SEC EDGARAaron G.l. Fletcher, Board member
- 22SEC EDGARHarlan F. Weisman, Board member
- 23SEC EDGARRandy H. Thurman, Board member
- 24SEC EDGARRobert S. Mills, Board member
- 25SEC EDGARStephen Rocamboli, Board member
- 26